Alex Rampotas

Exciting times for mutCALR MPNs - lovely data from the ET cohort presented in late breaking abstract at @EHA_Hematology. Rapid platelet control after just 2 doses with 89% of patients benefitting from a molecular response with INCA033989. @mpnvoice.bsky.social @mpnrf.bsky.social @mpnhv.bsky.social

Check our commentary on the amazing work by Falgas et all on developing a TIM-3 armored CAR-T therapy

🚨Very excited to see our work with Prof Claire Roddie out in @bloodjournal.bsky.social

CAR-T has revolutionized treatment for B-ALL, but what’s next? We discuss innovations, challenges, and the road ahead.

🔗 ashpublications.org/blood/articl...
#Leukemia #CARTcell #Hematology

We are recruiting!! Ads now live for a Data Coordinator and 2 Research Assistants/biobankers to join a new @ludwigcancer.bsky.social - @imm.ox.ac.uk joint initiative to prevent progression from early- to advanced blood cancer. Joint posts with Adam Mead+others in Oxford Ludwig. Links below

Fantastic news and very well deserved award!!! It has been amazing working together

The Road Less Traveled: T Cell-Engaging Immunotherapies for Myeloid Malignancies Bhagwat AS, Torres L, Shestova O, . Cytokine-mediated CAR T therapy resistance in AML. Nat Med. Published online September 27, 2024. PubMed

A very nice Sunday read on the challenged CAR-T cells face in tackling myeloid malignancies by Prof Beth Psaila and Zoe Wong

ashpublications.org/thehematolog...

Bye bye, bispecific?

Check out our commentary on the development of a CD19/BCMA dual targeting CAR-T for non-Hodgkin Lymphoma led by Bachiller et al.

Co-transduction for the win! Link below ⬇️ for free access authors.elsevier.com/a/1kIWB5QliS...

Many thanks for highlighting our work on CAR-T for Myelofibrosis! It has been a great meeting in San Diego #ASH24

ashpublications.org/ashnewsdaily...

As we’re coming towards the end of #ASH2024 I’d like to express my gratitude for the great science, company and feedback! @antoniorromera.bsky.social @alexrampotas.bsky.social @bethpsaila.bsky.social

It was great pleasure. Amazing meeting with great MPN research presented

Amazing presentation by Camelia Benlabiod (@beth_psaila / Caroline Marty lab) on the biology of calreticulin driven myelofibrosis in an immunocompetent mouse model #ASH24 #MPNsm

Looking forward to presenting our result and discussing all about CAR-T cell therapy for mutated calreticulin myelofibrosis #ASH24 Do join!

Thank you so much!!

Thank you so much!!

Thank you so much!!

You have been telling us why you chose #hematology and what inspires you each day. Your answers are becoming art!🎨 See it live in the Hall A lobby. #ASH24 #Hemesky

Thank you 🙏🙏

Very eloquent presentation by Antonio Romera from @bethpsaila.bsky.social lab on megakaryocyte biology and ability to take on DNA damage! Fantastic work #ASH24

You can hear all about it on Monday at 14:45.

With the support of @bloodcanceruk.bsky.social and the MRC, we are bringing this novel CAR-T cell therapy for myelofibrosis ever closer to the clinic #MPNsm

Very honoured to receive the ASH-BSH abstract achievement award

The result of the tremendous work by so many talented people who I had the privilege to work with
Zoe Wong, Isaac Gannon, @bethpsaila.bsky.social, Claire Roddie, Martin Pule and many more

#ASH24

Very pleased to present the results of a UK wide collaborative study on real world efficacy and safety of Momelotininb
- >60% anaemia responses at 6 months
-G1-2 peripheral neuropathy (15%)
-unexpected thrombocytosis (?hepcidin dysregulation due to AVCR1 inhibition)
#ASH24 @bethpsaila.bsky.social

Sunrise and moonset beyond the Coronado Bridge on a beautiful run around San Diego bay this morning

Attending #ASH24 and missing my baby boy. At least I can get him on my cup of coffee

Off to #ASH24. Books/music/movies all ready for 12h of economy flight 💪

Really proud of our physio Steph! Thank you to UK Haemophilia Society, Ben and others for this lovely recognition of her care and support! @ouhospitals.bsky.social www.ouh.nhs.uk/news/article...

Very nice review. As we have more options for myelofibrosis the choice of the right JAKi at the right time becomes ever more important

Do swing by to hear: (1) @antoniorromera.bsky.social present his fascinating work on how megakaryocytes tolerate whole genome duplication, implications for genome integrity & cancer evolution

and also not to be missed - Ros Cooper and Dan Royston's oral abstract 'mapping the human bone marrow in MPNs using Spatial Transcriptomics'

(3) Camelia Benlabiod presents her work from her PhD with Caroline Marty & Isabelle Plo @ Gustave Roussy on dissecting the cell-of-origin of mutCALR driven MPNs, and how del52 and ins5 elicit different signalling responses